MedPath

ABACAVIR/LAMIVUDINA GLENMARK 600 MG/300 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG

ABACAVIR/LAMIVUDINA GLENMARK 600 MG/300 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG

Commercialized
Register Number

82591

Prescription Type

Diagnóstico Hospitalario

Authorization Date

Nov 12, 2017

Dosage Form

COMPRIMIDO RECUBIERTO CON PELÍCULA

Route: VÍA ORAL

Product Details

Detailed information about this CIMA AEMPS approved pharmaceutical product.

Basic Information

Key regulatory and product classification details

Regulatory Details

Register Number82591
EMA Approved
No

Drug Classification

Generic
Yes
Orphan
No
Biosimilar
No
Commercialized
Yes
CIMA AEMPS Classification

INGREDIENTS (2)

ABACAVIR CLORHIDRATOActive
Quantity: 676.401 mg
Name: ABACAVIR CLORHIDRATO
LAMIVUDINAActive
Quantity: 300 mg
Name: LAMIVUDINA

ATC CLASSIFICATION (3)

J05A
J05AR
J05AR02

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.